psoriatic%20arthritis
PSORIATIC ARTHRITIS
Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.

Psoriatic Arthritis References

  1. Gossec L, Smolen JS, Gaujoux-Viala C, et al; European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012 Jan;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350. PMID: 21953336
  2. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermat. 2008 May;58(5):851-864. doi: 10.1016/j.jaad.2008.02.040. PMID: 18423261
  3. Kyle S, Chandler D, Griffiths M, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology. 2005 Mar;44(3):390-397. PMID: 15695305
  4. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009 Sep;68(9):1387-1394. doi: 10.1136/ard.2008.094946. PMID: 18952643
  5. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78. PMID: 4581554
  6. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-2673. PMID: 16871531
  7. Voorhees AV, Feldman SR, Koo JYM, et al. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. The National Psoriasis Foundation; 2009
  8. MedWormhttp://www.medworm.com/rss/index.php/Allergy-%26-Immunology/3/http://www.medworm.com/rss/medicalfeeds/specialities/Allergy-Immunology.xml
  9. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  10. Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults. SIGN. http://www.sign.ac.uk. 2010. Accessed 17 Jul 2011
  11. National Institute for Health and Care Excellence. Golimumab for the treatment of psoriatic arthritis. NICE. http://www.nice.org.uk/. 2011
  12. Coates L, Tillett W, Chandler P, et al. The 2012 British Society for Rheumatology guidelines for the treatment of psoriatic arthritis with biologicals. http://www.rheumatology.org.uk/includes/documents/cm_docs/2012/b/bsr_guidelines_2012_treatment_of_psoriatic_arthritis_with_biologics.pdf. 2012. Accessed 24 Jul 2013
  13. National Institute for Health and Care Excellence. Review of TA199; Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (includes a review of NICE technology appraisal guidance 104 and 125), and TA220; Golimumab for the treatment of psoriatic arthritis. NICE. http://www.nice.org.uk/. 2013
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).